Questcor Pharmaceuticals, Inc. (Questcor) is a pharmaceutical company focused on diseases and disorders. Questcor’s primary drug is H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved by the United States Food and Drug Administration (FDA) for the treatment of a variety of diseases and disorders. Acthar is also used in treating patients with infantile spasms (IS), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder, but is not approved for the treatment of either disorder. Acthar is approved to induce a diuresis or a remission of proteinuria in the nephrotic syndrome (NS) without uremia of the idiopathic type or that due to lupus erythamatosus. The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia. As of December 31, 2009, Acthar is approved in the United States for the treatment of multiple sclerosis (MS) exacerbations, nephrotic syndrome and many other conditions.
H.P. Acthar Gel
H.P. Acthar Gel is a natural source injectable preparation containing adrenocorticotropic hormone (ACTH). Acthar is specially formulated to provide prolonged release after intramuscular or subcutaneous injection. A primary mechanism of action for Acthar is the stimulation of the adrenal cortex to secrete endogenous corticosteroids, including cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Acthar is indicated for use in acute exacerbations of MS and is prescribed for patients that have MS and experience debilitating, episodic flares. It promotes Acthar for the treatment of exacerbations of MS. In addition to being indicated for the treatment of exacerbations of MS and nephrotic syndrome, Acthar has over 50 other labeled indications and uses in certain endocrine disorders, rheumatic disorders, collagen diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, and gastrointestinal diseases.
Doral is a commercial product indicated for the treatment of insomnia. Doral has a shelf life of 60 months from the date of manufacture.
Questcor Pharmaceuticals, Inc., founded in 1990 and headquartered in Union City, California, USA, is a specialty pharmaceutical company that focuses on novel therapeutics for the treatment of diseases and disorders of the central nervous system (CNS). Questcor currently owns and markets two commercial CNS products, H.P. Acthar Gel and Doral.
H.P. Acthar Gel is a natural source, highly purified preparation of the adrenal corticotropin hormone (ACTH), which Questcor acquired in July 2001. Unlike synthetic ACTH, Acthar is specially formulated to provide prolonged release after intramuscular or subcutaneous injection. It works by stimulating the adrenal cortex to secrete the natural endogenous corticosteroids, including cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Acthar is used in a wide variety of conditions, including the treatment of periodic flares associated with multiple sclerosis (MS), infantile spasm (IS), and various forms of arthritis (collectively called joint pain).
Doral is a commercial product indicated for the treatment of insomnia, characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Sleep disturbance and insomnia is a very common side effect of many neurological diseases and disorders such as MS, epilepsy, Parkinson’s disease, and Alzheimer’s disease and is a critical concern of Questcor’s targeted physicians. Questcor purchased the rights in the United States to Doral from MedPointe pursuant to an assignment and assumption agreement made in May 2006.
Group or Branch:
GAMETECH ARIZONA CORPORATION
3260, Whipple Road 94587, UNION CITY, CA, UNITED STATES OF AMERICA
+1 510 400 0700
+1 510 400 0799